MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ctrv.2016.11.015

Медицинская библиотека · Cancer treatment reviews · 2016

Rituximab: 13 open questions after 20years of clinical use.

Pavanello Francesca, Zucca Emanuele, Ghielmini Michele

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Rituximab improved the prognosis of all B-cell derived lymphoproliferative diseases, but despite 20years of intensive use, it remains a drug with a number of still obscure characteristics and unanswered questions. These include the mechanism of action and of resistance, the optimal schedule, the interaction with chemotherapy, as well as predictive factors for response rate and duration. Despite being very well tolerated, the question of its long term side effects and the risks of the administration near to a pregnancy have only recently been addressed. Also the indications are still not all clear: rituximab induces remissions as a single agent and improves the effect of chemotherapy, but its use as maintenance or as a substitute for watch and wait is still debated. Also, it is still unclear if its efficacy derives at least partly by reducing the risk of histological transformation in indolent NHL and reducing the risk of CNS relapse in aggressive NHL. Finally, despite of 20years of research, it is still unclear if rituximab can be efficiently substituted by biosimilars or new anti-CD20 antibodies. In this review we address all these questions and analyze the literature addressing these aspects.

Для цитирования: Pavanello Francesca, Zucca Emanuele, Ghielmini Michele. Rituximab: 13 open questions after 20years of clinical use.. Cancer treatment reviews. 2016. DOI: 10.1016/j.ctrv.2016.11.015.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.